0000899243-20-028184.txt : 20201014
0000899243-20-028184.hdr.sgml : 20201014
20201014163008
ACCESSION NUMBER: 0000899243-20-028184
CONFORMED SUBMISSION TYPE: 3/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200729
FILED AS OF DATE: 20201014
DATE AS OF CHANGE: 20201014
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Miller Edward
CENTRAL INDEX KEY: 0001619252
FILING VALUES:
FORM TYPE: 3/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39409
FILM NUMBER: 201239308
MAIL ADDRESS:
STREET 1: C/O ALEXION PHARMACEUTICALS, INC
STREET 2: 352 KNOTTER DRIVE
CITY: CHESHIRE
STATE: CT
ZIP: 06410
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Allovir, Inc.
CENTRAL INDEX KEY: 0001754068
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 831971007
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
BUSINESS PHONE: (617) 433-2605
MAIL ADDRESS:
STREET 1: 139 MAIN STREET, SUITE 500
CITY: CAMBRIDGE
STATE: MA
ZIP: 02142
FORMER COMPANY:
FORMER CONFORMED NAME: ViraCyte, Inc.
DATE OF NAME CHANGE: 20180924
3/A
1
doc3a.xml
FORM 3/A SUBMISSION
X0206
3/A
2020-07-29
2020-07-30
0
0001754068
Allovir, Inc.
ALVR
0001619252
Miller Edward
C/O ALLOVIR, INC.
139 MAIN STREET, SUITE 500
CAMBRIDGE
MA
02142
0
1
0
0
General Counsel
Common Stock
207565
D
Common Stock
124538
I
By Trust
This amendment on Form 3/A to the Form 3 originally filed on July 30, 2020 (the "Original Form 3") is being filed solely to include 124,538 shares of Common Stock held indirectly by the Reporting Person's trust, which were incorrectly reported as directly held by the Reporting Person on the Original Form 3. This amendment does not impact the Reporting Person's Table II holdings as reported in the Original Form 3.
Shares held by The Miller Family 2019 Irrevocable Dynasty Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
/s/ Edward Miller
2020-10-14